French biotech Osivax announced that its lead influenza vaccine OVX836 did not meet its pre-specified primary endpoint in a Phase 2b trial, though the company reported a first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes. Osivax plans to advance a combination strategy for next-generation seasonal influenza vaccines.
Bangladesh is considering clinical trials for a dengue vaccine after hundreds of deaths and thousands of hospitalizations from the mosquito-borne disease. The outbreak has worsened through September, with at least 233 deaths reported and experts warning that weather conditions could fuel further spread.
A four-dose series of an investigational Lyme disease vaccine demonstrated safety and tolerability in children and teens aged 5-17 years in phase 3 randomized controlled trial results presented at the American Academy of Pediatrics 2026 National Conference. The development comes as drugmakers race to create effective defenses against Lyme disease amid intensifying tick seasons.
Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.
Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.
British researchers have conducted the first successful clinical trials of vaccines that do not require refrigeration, a breakthrough that could address the problem of half of all vaccines being discarded due to cold chain failures.
Moderna has initiated a Phase 1 clinical trial in Canada of mRNA-1469, an experimental vaccine targeting Bundibugyo ebolavirus, a strain of Ebola that has killed over 1,650 people and currently has no approved vaccine. Health Canada has authorized the trial and the first participants have already been vaccinated.
Hilleman Laboratories, a Singapore-based partnership between Merck and Wellcome, is preparing to produce doses of an experimental vaccine targeting the rare Bundibugyo strain of Ebola amid a fast-spreading outbreak in the Democratic Republic of Congo.
Oxford University researchers administered the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola to a UK volunteer, as the deadly outbreak in the Democratic Republic of Congo has now killed over 1,000 people. Separate studies suggest existing Ebola vaccines may offer some cross-protection against this rare strain.
The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.
The University of Oxford has begun the first human trial of a vaccine targeting Bundibugyo ebolavirus, accelerating efforts to combat an ongoing outbreak in the Democratic Republic of Congo. A US patient infected in Congo is being treated at a German hospital.
The Democratic Republic of Congo's 17th Ebola epidemic has now claimed at least 506 lives out of 1,561 confirmed cases, according to health officials. The outbreak is caused by the Bundibugyo virus strain, for which no vaccine or approved treatment currently exists, and frontline health workers are threatening to strike.
New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.
India has approved new tuberculosis vaccines for adolescents, backed by a large, independent Phase III clinical trial led and funded by public science institutions. The vaccines represent a significant breakthrough in TB prevention, though officials note they are not a complete solution.
Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.